Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials

被引:12
|
作者
Canafax, Daniel M. [2 ]
Bhanegaonkar, Abhijeet [3 ]
Bharmal, Murtuza [4 ]
Calloway, Michael [1 ]
机构
[1] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA
[2] XenoPort Inc, Santa Clara, CA USA
[3] W Virginia Univ, Sch Pharm, Morgantown, WV 26506 USA
[4] Quintiles, Rockville, MD USA
关键词
QUALITY-OF-LIFE; MEDICAL OUTCOMES; SYNDROME RLS; EPIDEMIOLOGY; DIAGNOSIS; DISEASE; SCALE;
D O I
10.1186/1471-2377-11-48
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Because of the subjective nature of Restless Legs Syndrome (RLS) symptoms and the impact of these symptoms on sleep, patient-reported outcomes (PROs) play a prominent role as study endpoints in clinical trials investigating RLS treatments. The objective of this study was to validate a new measure, the Post Sleep Questionnaire (PSQ), to assess sleep dysfunction in subjects with moderate-to-severe RLS symptoms. Methods: Pooled data were analyzed from two 12-week, randomized, placebo-controlled trials of gabapentin enacarbil (N = 540). At baseline and Week 12, subjects completed the PSQ and other validated health surveys: IRLS Rating Scale, Clinical Global Impression of Improvement (CGI-I), Profile of Mood States (POMS), Medical Outcomes Study Scale-Sleep (MOS-Sleep), and RLS-Quality of Life (RLSQoL). Pooled data were used post hoc to examine the convergent, divergent, known-group validity and the responsiveness of the PSQ. Results: Convergent validity was demonstrated by significant correlations between baseline PSQ items and total scores of IRLS, POMS, RLSQoL, and the MOS-Sleep Scale (p = 0.007 each). Divergent validity was demonstrated through the lack of significant correlations between PSQ items and demographic characteristics. Correlations (p < 0.0001) between RLS severity groups and PSQ items demonstrated known-group validity. Mean changes in investigator-and subject-rated CGI-I scores for each PSQ item (p < 0.0001) demonstrated the PSQ's responsiveness to patient change as reported by their care provider. Conclusions: Although these analyses were potentially limited by the use of clinical trial data and not prospective data from a study conducted solely for validation purposes, the PSQ demonstrated robust psychometric properties and is a valid instrument for assessing sleep and sleep improvements in subjects with moderate-to-severe RLS symptoms.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Tolerability of Gabapentin Enacarbil in Subjects with Restless Legs Syndrome (RLS)
    Lee, Daniel
    Ziman, Ronald
    Perkins, A. Thomas
    Poceta, J. Steven
    Walters, Arthur S.
    Barrett, Ronald W.
    NEUROLOGY, 2009, 72 (11) : A337 - A337
  • [22] Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
    Berry-Kravis, Elizabeth
    Portes, Vincent Des
    Hagerman, Randi
    Jacquemont, Sebastien
    Charles, Perrine
    Visootsak, Jeannie
    Brinkman, Marc
    Rerat, Karin
    Koumaras, Barbara
    Zhu, Liansheng
    Barth, Gottfried Maria
    Jaecklin, Thomas
    Apostol, George
    von Raison, Florian
    SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (321)
  • [23] A double-blind, randomized, placebo-controlled exploratory study of SYN118 in restless legs syndrome
    Benes, H.
    Eisensehr, I.
    Hoegl, B.
    Meya, U.
    Sarnecki, M.
    Kohnen, R.
    Oertel, W.
    MOVEMENT DISORDERS, 2011, 26 : S363 - S363
  • [24] Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome
    Bliwise, DL
    Freeman, A
    Ingram, CD
    Rye, DB
    Chakravorty, S
    Watts, RL
    SLEEP MEDICINE, 2005, 6 (02) : 141 - 147
  • [25] Botulinum Toxin in Restless Legs Syndrome-A Randomized Double-Blind Placebo-Controlled Crossover Study
    Mittal, Shivam Om
    Machado, Duarte
    Richardson, Diana
    Dubey, Divyanshu
    Jabbari, Bahman
    TOXINS, 2018, 10 (10):
  • [26] Lowest effective dosing of pramipexole for restless legs syndrome: Results from three double-blind clinical trials
    Lainey, Eric
    Peker, Yuksel
    Albrecht, Stefan
    Koester, Juergen
    CHEST, 2007, 132 (04) : 504S - 504S
  • [27] Monitoring for sudden onset of sleep in placebo-controlled trials of pramipexole for restless legs syndrome
    Walters, Arthur
    Lainey, Eric
    Koester, Juergen
    NEUROLOGY, 2007, 68 (12) : A255 - A255
  • [28] Ropinirole in the treatment of patients with restless legs syndrome: A US-based randomized, double-blind, placebo-controlled clinical trial
    Bogan, RK
    Fry, JM
    Schmidt, MH
    Carson, SW
    Ritchie, SY
    MAYO CLINIC PROCEEDINGS, 2006, 81 (01) : 17 - 27
  • [29] Validation of the Post-Sleep Questionnaire (PSQ) for Assessment of Sleep in Subjects with Restless Legs Syndrome (RLS)
    Canafax, Daniel
    Bhanegaonkar, Abhijeet
    Bharmal, Murtuza
    Calloway, Michael
    NEUROLOGY, 2009, 72 (11) : A340 - A341
  • [30] VALIDATION OF THE POST-SLEEP QUESTIONNAIRE (PSQ) FOR ASSESSMENT OF SLEEP IN SUBJECTS WITH RESTLESS LEGS SYNDROME (RLS)
    Canafax, D.
    Bhanegaonkar, A.
    Bharmal, M.
    Calloway, M.
    SLEEP, 2009, 32 : A303 - A304